Rigel Pharmaceuticals, Inc.
RIGL
$42.58
$1.794.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 276.52M | 299.50M | 294.02M | 282.08M | 267.92M |
| Total Other Revenue | 265.00K | 265.00K | 265.00K | -- | -- |
| Total Revenue | 276.79M | 299.77M | 294.28M | 282.08M | 267.92M |
| Cost of Revenue | 67.51M | 56.35M | 52.92M | 47.70M | 49.80M |
| Gross Profit | 209.27M | 243.41M | 241.37M | 234.38M | 218.12M |
| SG&A Expenses | 122.22M | 118.84M | 115.90M | 115.43M | 113.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.74M | 175.19M | 168.82M | 163.13M | 163.33M |
| Operating Income | 87.05M | 124.58M | 125.47M | 118.95M | 104.59M |
| Income Before Tax | 85.58M | 121.97M | 121.83M | 114.34M | 99.14M |
| Income Tax Expenses | -236.33M | -242.26M | -245.20M | 1.04M | 1.32M |
| Earnings from Continuing Operations | 321.91 | 364.23 | 367.02 | 113.30 | 97.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 321.91M | 364.23M | 367.02M | 113.30M | 97.82M |
| EBIT | 87.05M | 124.58M | 125.47M | 118.95M | 104.59M |
| EBITDA | 89.70M | 126.99M | 127.88M | 121.37M | 107.01M |
| EPS Basic | 17.67 | 20.07 | 20.24 | 6.34 | 5.49 |
| Normalized Basic EPS | 2.93 | 4.23 | 4.24 | 4.00 | 3.48 |
| EPS Diluted | 16.33 | 18.73 | 18.92 | 6.17 | 5.41 |
| Normalized Diluted EPS | 2.74 | 4.05 | 4.08 | 3.89 | 3.43 |
| Average Basic Shares Outstanding | 73.20M | 72.54M | 71.94M | 71.38M | 70.94M |
| Average Diluted Shares Outstanding | 78.21M | 76.80M | 75.28M | 73.47M | 71.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |